Skip to content
Clinical Trials – home

Pitolisant: A Comprehensive Guide for Patients

2 / 5
trials open to patients / all trials
7+
Countries

In short

Pitolisant, a novel drug that acts as a histamine H3 receptor antagonist/inverse agonist, is being extensively studied in clinical trials for its potential to treat various sleep disorders and other conditions. This article explores the ongoing research into pitolisant's efficacy and safety across different patient populations, including those with narcolepsy, idiopathic hypersomnia, and autism spectrum disorders.

At a glance

Drug Name
Pitolisant (also known as BF2.649, Wakix)
Mechanism of Action
Histamine H3 receptor antagonist/inverse agonist
Conditions Studied
Narcolepsy (with and without cataplexy), Idiopathic Hypersomnia, Excessive Daytime Sleepiness, Restless Legs Syndrome, Autism Spectrum Disorders
Administration
Oral tablet, typically once daily in the morning
Dosage Range
4.45 mg to 35.6 mg (varies by study)
Primary Outcomes
Changes in excessive daytime sleepiness, frequency of cataplexy attacks, safety assessments
Patient Populations
Adults, children, and adolescents (depending on the study)
Study Designs
Randomized, double-blind, placebo-controlled trials; open-label studies

What is Pitolisant?

Pitolisant, also known by its brand name Wakix or BF2.649, is a medication that belongs to a class of drugs called histamine H3 receptor antagonists/inverse agonists. It is primarily used to treat excessive daytime sleepiness and cataplexy (sudden loss of muscle tone) in people with narcolepsy, a chronic sleep disorder.

What Conditions Does Pitolisant Treat?

Pitolisant is approved and being studied for several conditions:

  • Narcolepsy with or without cataplexy: This is the primary condition for which pitolisant is used. Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness and, in some cases, sudden loss of muscle tone (cataplexy).
  • Idiopathic Hypersomnia: A sleep disorder characterized by excessive daytime sleepiness despite normal or prolonged nighttime sleep.
  • Restless Legs Syndrome (RLS): A condition that causes an uncomfortable sensation and an urge to move the legs, typically in the evening or nighttime.
  • Autism Spectrum Disorder: Pitolisant is being studied for its potential effects on social responsiveness in children and adolescents with autism.

How Does Pitolisant Work?

Pitolisant works by targeting the histamine system in the brain. Specifically, it acts as an antagonist/inverse agonist at histamine H3 receptors. This means it blocks these receptors and may also reverse their normal activity. By doing so, pitolisant increases the release of histamine in the brain, which helps promote wakefulness and alertness.

Dosage and Administration

Pitolisant is typically taken orally once daily in the morning upon wakening. The dosage can vary depending on the condition being treated and individual patient factors. In clinical trials, the following dosing strategies have been observed:

  • For narcolepsy in adults: Starting dose of 8.9 mg, which can be increased weekly up to a maximum of 35.6 mg.
  • For children and adolescents: Dosing is being studied and may range from 5 mg to 40 mg per day.

It's important to note that dosage should always be determined by a healthcare provider based on individual patient needs and responses.

Ongoing Clinical Trials

Pitolisant is currently being studied in several clinical trials to explore its effectiveness in various conditions:

  • Long-term safety and effectiveness in idiopathic hypersomnia: A study to assess the long-term effects of pitolisant in patients with idiopathic hypersomnia.
  • Refractory Restless Legs Syndrome: An open-label trial to evaluate pitolisant as an adjunct therapy for patients with RLS who haven't responded adequately to standard treatments.
  • Autism Spectrum Disorders in children and adolescents: A study to investigate the effect of pitolisant on social responsiveness in young people with autism.
  • Type 1 Diabetes: A study to assess the safety, tolerability, and effects of pitolisant on blood sugar control in patients with Type 1 Diabetes.
  • Alcohol Use Disorder: A trial to test the effect of pitolisant on alcohol consumption and craving in heavy drinkers.

Potential Side Effects

As with all medications, pitolisant may cause side effects. Common side effects reported in clinical trials include:

  • Headache
  • Nausea
  • Insomnia
  • Anxiety

However, it's important to note that not everyone experiences side effects, and your doctor will monitor you closely for any adverse reactions.

Use in Special Populations

Pregnancy: A pregnancy registry has been established to study the effects of pitolisant exposure during pregnancy. This observational study aims to evaluate the safety of pitolisant use in pregnant women and their offspring.

Children and Adolescents: Clinical trials are ongoing to assess the safety and efficacy of pitolisant in pediatric populations, particularly for narcolepsy and autism spectrum disorders.

Questions people often ask

Conditions where Pitolisant is being studied

Each condition opens its own overview and trial list

Trials with Pitolisant

Recruiting trials first

See all 5 →
Quick filters
  • Participants:Children
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).